SSSimon Sauvé

Simon Sauvé

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Simon Sauvé has a total of 54 co-authors. Here are the top co-authors by number of shared publications:

  • Xuguang Li

    Centre for Oncology, Radiopharmaceuticals and Research, Biologic and Radiopharmaceutical Drugs Directorate, Health Products and Food Branch, Health Canada and World Health Organization Collaborating Center for Standardization and Evaluation of Biologicals, Ottawa, Canada

    5 shared publications
  • Annabelle Pfeifle

    Centre for Oncology, Radiopharmaceuticals and Research, Biologic and Radiopharmaceutical Drugs Directorate, Health Products and Food Branch, Health Canada and World Health Organization Collaborating Center for Standardization and Evaluation of Biologicals, Ottawa, ON K1A 0K9, Canada

    3 shared publications
  • Levi Tamming

    Department of Chemistry and Biomolecular Sciences, University of Ottawa, Ottawa, Canada

    3 shared publications
  • Aaron Farnsworth

    Centre for Biologics Evaluation, Biologic and Radiopharmaceutical Drugs Directorate, HPFB, Health Canada and WHO Collaborating Center for Standardization and Evaluation of Biologicals, Ottawa, ON, Canada

    2 shared publications
  • Barry Lorbetskie

    Center for Oncology, Radiopharmaceuticals and Research, Biologic and Radiopharmaceutical Drugs Directorate, Health Products and Food Branch, Health Canada, Ottawa, ON K1A 0K9, Canada

    2 shared publications
  • Caroline Gravel

    Centre for Oncology, Radiopharmaceuticals and Research, Biologic and Radiopharmaceutical Drugs Directorate, Health Products and Food Branch, Health Canada and World Health Organization Collaborating Center for Standardization and Evaluation of Biologicals, Ottawa, ON K1A 0K9, Canada

    2 shared publications

Latest Publications

  • Open Access

    Advancing Reversed-Phase Chromatography Analytics of Influenza Vaccines Using Machine Learning Approaches on a Diverse Range of Antigens and Formulations

    by Barry Lorbetskie, Narges Manouchehri, Michel Girard, Simon Sauvé, Huixin Lu

    One concern in the yearly re-formulation of influenza vaccines is the time-consuming manufacturing of vaccine potency reagents, particularly for emergency responses. The continuous evaluation of modern techniques such as reversed-phase (RP) chromatography is an asset for streamlining this process. One challenge with RP methods, however, is the need to re-optimize methods for antigens that show poor separation, which can be highly dependent on analyst experience and available data. In this study, we leveraged a large RP dataset of influenza antigens to explore machine learning (ML) approaches of classifying challenging separations for computer-assisted method re-optimization across years, products, and analysts. Methods: To address recurring chromatographic issues—such as poor resolution, strain co-elution, and signal absence—we applied data augmentation techniques to correct class imbalance and trained multiple supervised ML classifiers to distinguish between these peak profiles. Results: With data augmentation, several ML models demonstrated promising accuracy in classifying chromatographic profiles according to the provided labels. These models effectively distinguished patterns indicative of separation issues in real-world data. Conclusions Our findings highlight the potential of ML as a computer assisted tool in the evaluation of vaccine quality, offering a scalable and objective approach to chromatogram classification. By reducing reliance on manual interpretation, ML can expedite the optimization of analytical methods, which is particularly needed for rapid responses. Future research involving larger, inter-laboratory datasets will further elucidate the utility of ML in vaccine analysis.


  • Open Access

    Borrelia burgdorferi Strain-Specific Differences in Mouse Infectivity and Pathology

    by Annabelle Pfeifle, Rose Anderson-Duvall, Levi A. Tamming, Wanyue Zhang, Sathya N. Thulasi Raman, Caroline Gravel, Jianguo Wu, Heather Coatsworth, Maarten J. Voordouw, Xu Zhang, et al.

    Lyme disease (LD), caused by infection with the tick-borne bacteria, Borrelia burgdorferi, is associated with a wide array of symptoms in human patients. Variations in clinical manifestations are thought to be influenced by genetic differences among B. burgdorferi strains. In this study, we evaluated the infectivity, tissue bacterial load, pathology, and immunogenicity of five strains of B. burgdorferi sensu stricto (297 Ah130, Bb16-54, B31-A3, Bb16-126, JD1) in female C3H/HeN mice at three infectious doses (104, 105, 106 spirochetes). We found that strains Bb16-126 and JD1 were the most infectious, resulting in 100% infection across all the tested doses. Strain Bb16-126 caused the highest bacterial burden in the heart tissue and significant carditis, whereas JD1 exhibited the lowest spirochete load in the heart and minimal carditis. In comparison, strain B31-A3 demonstrated the highest abundance in the tibiotarsal joint. Infection with all the strains induced severe lymph node hyperplasia, with JD1 producing the greatest increase in cellularity. Using a diagnostic C6 peptide ELISA, all the strains induced significant anti-C6 IgM and IgG antibody titers at 14 days post-infection; however, strain B31-A3 elicited the highest anti-C6 IgM titers. Our findings demonstrate the importance of strain diversity in shaping B. burgdorferi pathogenesis in a mouse model and provide insights for developing strain-specific diagnostic, therapeutic, and vaccine strategies.


  • Open Access

    The Expression Kinetics and Immunogenicity of Lipid Nanoparticles Delivering Plasmid DNA and mRNA in Mice

    by Wanyue Zhang, Annabelle Pfeifle, Casey Lansdell, Grant Frahm, Jonathon Cecillon, Levi Tamming, Caroline Gravel, Jun Gao, Sathya N. Thulasi Raman, Lisheng Wang, et al.

    In recent years, lipid nanoparticles (LNPs) have emerged as a revolutionary technology for vaccine delivery. LNPs serve as an integral component of mRNA vaccines by protecting and transporting the mRNA payload into host cells. Despite their prominence in mRNA vaccines, there remains a notable gap in our understanding of the potential application of LNPs for the delivery of DNA vaccines. In this study, we sought to investigate the suitability of leading LNP formulations for the delivery of plasmid DNA (pDNA). In addition, we aimed to explore key differences in the properties of popular LNP formulations when delivering either mRNA or DNA. To address these questions, we compared three leading LNP formulations encapsulating mRNA- or pDNA-encoding firefly luciferase based on potency, expression kinetics, biodistribution, and immunogenicity. Following intramuscular injection in mice, we determined that RNA-LNPs formulated with either SM-102 or ALC-0315 lipids were the most potent (all p-values < 0.01) and immunogenic (all p-values < 0.05), while DNA-LNPs formulated with SM-102 or ALC-0315 demonstrated the longest duration of signal. Additionally, all LNP formulations were found to induce expression in the liver that was proportional to the signal at the injection site (SM102: r = 0.8787, p < 0.0001; ALC0315: r = 0.9012, p < 0.0001; KC2: r = 0.9343, p < 0.0001). Overall, this study provides important insights into the differences between leading LNP formulations and their applicability to DNA- and RNA-based vaccinations.


  • Open Access

    Synthetic vaccine affords full protection to mice against lethal challenge of influenza B virus of both genetic lineages

    by Caroline Gravel, Abenaya Muralidharan, Amparo Duran, Adrian Zetner, Annabelle Pfeifle, Wanyue Zhang, Anwar Hashem, Levi Tamming, Aaron Farnsworth, Hugues Loemba, et al.


  • Resolving Isomeric Structures of Native Glycans by Nanoflow Porous Graphitized Carbon Chromatography–Mass Spectrometry

    by Yi-Min She, Roger Y. Tam, Xuguang Li, Michael Rosu-Myles, Simon Sauvé

    Characterization of the structural diversity of glycans by liquid chromatography-tandem mass spectrometry (LC MS/MS) remains an analytical challenge in large-scale glycomics applications due to the presence of heterogeneous composition, ubiquitous isomers, lability of post-translational glycan modifications, and complexity of data interpretation. High-resolution separation of glycan isomers differentiating from positional, linkage, branching and anomeric structures is often a prerequisite to ensure the comprehensive glycan identification. Here we developed a straightforward method using self-packed capillary porous graphitic carbon (PGC) columns for nanoflow LC MS/MS analyses of native glycans released from glycoproteins. The technique enables highly resolved chromatographic separation of over twenty high-mannose glycan isomers in ribonuclease B, and a diverse range of hybrid and complex-type sialoglycoforms of fetuin. The distinct structures of anomeric glycans, α2,3 and α2,6 linkage sialoglycan isomers were identified by the characteristic MS/MS fragment ions. A glycan sequencing strategy utilizing diagnostic ions and complementary fragments specific to branching residues was established to simplify the MS/MS data interpretation of closely related isomeric structures. To promote the PGC-LC-MS/MS-based method for glycome-wide applications, we extended analyses to native sulfoglycans from the egg-propagated and cell culture-derived influenza vaccines, and demonstrate the high-resolution separation and structural characterization of underivatized neutral and anionic glycoforms including oligomannosidic glycan anomers, sialoglycan linkage isomers, and regioisomers of afucosylated and fucosylated sulfoglycans containing sulfated-6-GlcNAc and sulfated-4-GalNAc residues.


  • Selective Capture and Determination of Receptor-Binding Hemagglutinin in Influenza Vaccine Preparations Using a Coupled Receptor-Binding/RP-HPLC Assay

    by Barry Lorbetskie, Anna-Maria Cunningham, Michèle Lemieux, Laura Durno, Aaron Farnsworth, Junzhi Wang, Changgui Li, Xuguang Li, Michel Gilbert, Simon Sauvé, et al.

    Influenza vaccine potency is determined by the quantification of immunologically active hemagglutinin capable of eliciting neutralizing antibodies upon immunization. Currently, the single radial immunodiffusion (SRID) method is the standard in vitro potency assay used for lot release of seasonal inactivated influenza vaccines. Despite the proven usage of SRID, significant limitations such as the time-consuming preparation of reagents and limited dynamic range warrant the need for the development of alternative potency assays. Such alternative approaches need to discriminate and quantify relevant hemagglutinin material, provide strain identity, and be independent of strain-specific and seasonal reagents. Herein, we present a proof of concept method that combines the capture of conformationally well-folded hemagglutinin via a sialic acid-binding step with the resolving power of reversed-phase high-performance liquid chromatography for strain identity and determination. Details of the protocol for the selective capture of receptor-binding hemagglutinin, its release from the receptor and its relative determination are presented. This approach was found to provide flexibility for the reagents to be used and was adaptable to varying strain composition of influenza vaccines. This proof-of-concept approach was developed as an antibody-independent methodology.


  • Fast and highly selective determination of hemagglutinin content in quadrivalent influenza vaccine by reversed-phase high-performance liquid chromatography method

    by Barry Lorbetskie, Nathalie Fortin, Laura Durno, Junzhi Wang, Changgui Li, Xuguang Li, Michel Girard, Simon Sauvé


  • Open Access

    Interactions between the Conserved Hydrophobic Region of the Prion Protein and Dodecylphosphocholine Micelles

    by Simon Sauvé, Daniel Buijs, Geneviève Gingras, Yves Aubin